|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 401/14 | |
| A61K 31/53 | |||
| A61K 31/55 | |||
| C07D 487/04 | |||
| A61P 35/00 |
| (11) | Number of the document | 3174869 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15747562.5 |
| Date of filing the European patent application | 2015-07-29 | |
| (97) | Date of publication of the European application | 2017-06-07 |
| (45) | Date of publication and mention of the grant of the patent | 2020-08-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2015/055737 |
| Date | 2015-07-29 |
| (87) | Number | WO 2016/016822 |
| Date | 2016-02-04 |
| (30) | Number | Date | Country code |
| 201462031583 P | 2014-07-31 | US |
| (72) |
HAO, Huaixiang, US
HUANG, Xizhong, US
TAM, Angela, US
KASIBHATLA, Shailaja, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | COMBINATION THERAPY OF A MET INHIBITOR AND AN EGFR INHIBITOR |
| COMBINATION THERAPY OF A MET INHIBITOR AND AN EGFR INHIBITOR |